TY - JOUR
T1 - High-risk infant follow-up
T2 - current practice and factors determining eligibility
AU - on behalf of the Newborn Brain Consortium
AU - Clifford, Danielle
AU - Steggerda, Sylke
AU - Maitre, Nathalie
AU - de Vries, Linda S.
AU - Murray, Deirdre M.
AU - Check, Jennifer
AU - Rego, Albertina
AU - Jayakumar, Srishti
AU - Colón-Díaz, Keimarisse
AU - Tremblay, Sophie
AU - Murray, Anne
AU - Roze, Elise
AU - Tuiskula, Anna
AU - Nuzum, Tatiana
AU - Stapleton, Iyshwarya
AU - Chiodin, Elisabetta
AU - van de Lagemaat, Monique
AU - Boronat-Gonzalez, Nuria
AU - Wickland, Jessica
AU - Nicoletti, Nicholas William
AU - Slaughter, Laurel A.
AU - Butler, Emma
AU - Rakshpaul, Sonal
AU - Pardo, Andrea C.
AU - Cordeiro, Catarina
AU - Kukka, Antti
AU - Keene, Jennifer C.
AU - Sadoo, Samantha
AU - Graça, André M.
AU - Armstrong, Jennifer
AU - Silveira, Rita C.
AU - Agarwal, Sonika
AU - Kidokoro, Hiroyuki
AU - Procianoy, Renato S.
AU - Goyal, Medha
AU - Afifi, Jehier
AU - Buchmayer, Julia
AU - Capizzi, Mariarita
N1 - Publisher Copyright:
© The Author(s) 2025.
PY - 2025
Y1 - 2025
N2 - Background: High-risk infant follow-up (HRIF) lacks universal definition. The aim of this study was to report current practice and factors used to identify eligibility for HRIF, yielding information which may provide a basis for future consensus. Methods: A survey was prepared for a workshop at the 15th International Newborn Brain Conference on prediction of outcome, which was subsequently distributed to all attendees (n = 426). Results: Follow-up was offered by 97% of respondents (n = 113/116). HRIF was offered to infants born <28 weeks by 47%, to those <32 weeks by two-thirds (66%) and to preterms based on neuroimaging by 54%. For infants born full-term, HRIF was offered by 88% in neonatal encephalopathy (NE) and 86% in neonatal stroke. HRIF continued most frequently until 24 months corrected (33.6%). For guiding prognosis in preterm infants, 22% (n = 25) selected neuroimaging as the most important factor. For NE, 54% (n = 63) selected neuroimaging findings as the most important factor in guiding prognosis and 14% (n = 16) selected EEG/aEEG. Social factors are not considered by 46% in determining HRIF eligibility. Conclusion: Significant variability in HRIF exists, without consensus. Awareness of factors predicting prognosis and the importance of social risk-factors must improve to allow accurate identification of those at highest risk. This information may act as a basis for future consensus on HRIF. Impact: There is no clear consensus on eligibility or duration of high-risk infant follow-up. We report current practice in, and factors used to identify eligibility for same, amongst attendees of the International Newborn Brain Conference. This information on international practice may provide a basis for future consensus. Given the importance of accurate prognostication in risk-stratification, we report participants’ awareness of the most important factors guiding prognosis. A disconnect between the impact of social factors on outcome and their consideration for eligibility of high-risk infant follow-up is noted. We propose the need for guidelines on follow-up of socially disadvantaged, medically high-risk infants.
AB - Background: High-risk infant follow-up (HRIF) lacks universal definition. The aim of this study was to report current practice and factors used to identify eligibility for HRIF, yielding information which may provide a basis for future consensus. Methods: A survey was prepared for a workshop at the 15th International Newborn Brain Conference on prediction of outcome, which was subsequently distributed to all attendees (n = 426). Results: Follow-up was offered by 97% of respondents (n = 113/116). HRIF was offered to infants born <28 weeks by 47%, to those <32 weeks by two-thirds (66%) and to preterms based on neuroimaging by 54%. For infants born full-term, HRIF was offered by 88% in neonatal encephalopathy (NE) and 86% in neonatal stroke. HRIF continued most frequently until 24 months corrected (33.6%). For guiding prognosis in preterm infants, 22% (n = 25) selected neuroimaging as the most important factor. For NE, 54% (n = 63) selected neuroimaging findings as the most important factor in guiding prognosis and 14% (n = 16) selected EEG/aEEG. Social factors are not considered by 46% in determining HRIF eligibility. Conclusion: Significant variability in HRIF exists, without consensus. Awareness of factors predicting prognosis and the importance of social risk-factors must improve to allow accurate identification of those at highest risk. This information may act as a basis for future consensus on HRIF. Impact: There is no clear consensus on eligibility or duration of high-risk infant follow-up. We report current practice in, and factors used to identify eligibility for same, amongst attendees of the International Newborn Brain Conference. This information on international practice may provide a basis for future consensus. Given the importance of accurate prognostication in risk-stratification, we report participants’ awareness of the most important factors guiding prognosis. A disconnect between the impact of social factors on outcome and their consideration for eligibility of high-risk infant follow-up is noted. We propose the need for guidelines on follow-up of socially disadvantaged, medically high-risk infants.
UR - https://www.scopus.com/pages/publications/105011883169
U2 - 10.1038/s41390-025-04154-2
DO - 10.1038/s41390-025-04154-2
M3 - Article
C2 - 40494865
AN - SCOPUS:105011883169
SN - 0031-3998
JO - Pediatric Research
JF - Pediatric Research
ER -